Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297725 | 0.85 | MAPK14 (0.44) | FFAR2LMNAALDH1A1METMAPT | |
| SCHEMBL29077942 | 0.85 | MAPK14 (0.44) | FFAR2LMNAALDH1A1METMAPT | |
| SCHEMBL27211133 | 0.85 | IDO1 (0.41) | FFAR2TDP1LMNAALDH1A1MET | |
| SCHEMBL27211370 | 0.84 | MRGPRX2 (0.42) | FFAR2TDP1ACACB | |
| SCHEMBL29564440 | 0.84 | MRGPRX2 (0.42) | FFAR2TDP1ACACB | |
| SCHEMBL31132558 | 0.83 | IDO1 (0.42) | FFAR2TDP1LMNAALDH1A1IDO1 | |
| SCHEMBL24298066 | 0.82 | FFAR2 (0.45) | FFAR2LMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL27211262 | 0.81 | GCK (0.46) | TDP1LMNAALDH1A1METL3MBTL1 | |
| SCHEMBL24932158 | 0.80 | ALDH1A1 (0.50) | TDP1LMNAALDH1A1METKDM4E | |
| SCHEMBL27210967 | 0.80 | ALDH1A1 (0.40) | FFAR2TDP1LMNAALDH1A1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | FFAR2 541/4885TDP1 4070/4885LMNA 1856/4885 |
| US-20220112174-A1 | MRGX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | FFAR2 541/4885TDP1 4070/4885LMNA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.